The CLI with 131I-PD-L1-Mab is not only considered as a prominent noninvasive imaging method that is accessible to assess and monitor dynamic PD-L1 expression in tumor lesions but is also used to clinically screen potential patients who can benefit from PD-1/ PD-L1 targeted therapy. This evidence concerns the gene PDCD1 and neoplasm.